Skip to content

Pudendal Nerve Block for Catheter-related Bladder Discomfort Prevention

Comparison of Pudendal Nerve Block With Ropivacaine and Intravenous Tramadol for Prevention of Catheter-related Bladder Discomfort: a Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02683070
Enrollment
94
Registered
2016-02-17
Start date
2016-03-31
Completion date
2018-08-31
Last updated
2016-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catheter Site Discomfort

Keywords

Catheter-related bladder discomfort, Pudendal nerve block, Tramadol, Randomized controlled trial, catheter-related bladder discomfort prevention

Brief summary

Catheter-related bladder discomfort (CRBD) is not uncommon in male patients under general anesthesia, and it may cause patient agitation and exacerbated postoperative pain. In this study, the investigators will enroll male patients undergoing elective prostate surgery with urinary catheterization after anesthetic induction, and compare the efficacy of pudendal nerve block (PNB) and intravenous tramadol in prevention of CRBD.

Detailed description

The PNB trial is an investigator-initiated, prospective, randomized controlled trial that will test the superiority of pudendal nerve block with 0.33% ropivacaine to intravenous tramadol 1.5mg/kg for CRBD prevention. A total of 94 patients undergoing elective prostate surgery at lithotomy position with urinary catheterization (16 G Fr Foley catheter) after anesthetic induction under general anesthesia will be enrolled at West China Hospital of Sichuan University. Patients will be divided randomly into two groups: The PNB group: patients will be given bilateral pudendal nerve block with 30ml of 0.33% ropivacaine (15ml for each side) after the completion of surgery before extubation. The TRAM group: patients will be given tramadol of 1.5mg/kg after the completion of surgery before extubation. All patients will be evaluated by a research nurse who were blinded to the group assignments for outcomes at 0, 1, 2, 4, and 6h after patients' arrival in PACU, and after extraction of urinary catheter. The primary outcome is the incidence of postoperative CRBD. The secondary outcomes include the severity of postoperative CRBD, postoperative tramadol requirement and number of patients with requiring postoperative tramadol, numeric rating scale (NRS) for postoperative pain, postoperative sufentanil requirement and number of patients with requiring postoperative sufentanil, postoperative side effects, and acceptance of indwelling urinary catheter after extraction of the catheter. All primary and secondary endpoints will be analyzed on an intent-to-treat basis. Analyses are performed with the use of SPSS 18.0 software. The Student-t test is used to analyze demographic data in the two groups. The incidence of CRBD and side effects between groups are analyzed by Chi-square test, whereas the severity of CRBD (mild, moderate, and severe) is analyzed by Fisher's exact test. NRS scale is analyzed by the Mann-Whitney test. Postoperative tramadol and sufentanil requirement is analyzed by Z test, and the number of patients requiring tramadol for CRBD rescue treatment and sufentanil for postoperative pain will be analyzed with Fisher's exact test. A P value\<0.05 is considered significant.

Interventions

Bilateral pudendal nerve block with 30ml of 0.33% ropivacaine (15ml for each side) after the completion of surgery before extubation

DRUGIntravenous tramadol

Intravenous tramadol of 1.5mg/kg after the completion of surgery before extubation

Sponsors

West China Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients aged 18years to 75years. * American Society of Anesthesiologists (ASA) physical status I, II, or Ⅲ. * Undergoing elective prostate surgery at lithotomy position with urinary catheterization after anesthetic induction under general anesthesia. * Glasgow Coma Scale (GCS) score of 15. Ability to communicate.

Exclusion criteria

* History of bladder dysfunction, such as over active bladder (OAB, urinary frequency: more than three times in the night or more than eight times in 24 h). * History of bladder outflow obstruction. * Neurogenic bladder. * Impaired renal function. * Coagulopathy. * Known allergies to any anesthetic agent. * Family history of malignant hyperthermia. * Impairment of communication or cognition. * Psychopathy. * Active participation in another trial where the primary endpoint follow-up is ongoing. * Unwillingness or inability to comply with protocol procedures.

Design outcomes

Primary

MeasureTime frameDescription
The incidence of postoperative CRBD1 dayPatients complained about postoperative CRBD

Secondary

MeasureTime frameDescription
Postoperative tramadol requirement1 dayWhen moderate or severe CRBD is reported, intravenous tramadol 1.5mg/kg will be administered as a rescue treatment to reduce the bladder discomfort, and tramadol requirement will be recorded and compared.
Numeric rating scale (NRS) for postoperative pain.1 dayPatients will be asked for evaluating pain intensity by themselves using this single 11-point numeric scale ranged between 0 to 10, where 0 represents no pain and 10 represents worst imaginable pain \[17\]. If the patient complains about pain with NRS greater than 4, intravenous sufentanil 5 μg will be administered as rescue analgetic treatment.
The severity of postoperative CRBD1 dayIt's assessed according to the following scaling system: no CRBD indicates that there are no complaints of CRBD at all; mild indicates that complaints of CRBD exist only if the patient was asked about it; moderate indicates that patients complain of CRBD spontaneously; and severe indicates that CRBD causes a spontaneous behavioral response such as flailing limb, strong vocal response, or attempt to pull out the catheter.
Incidences of postoperative side effects1 daySide effects include postoperative nausea/vomiting (PONV), dizziness, sedation, and dry mouth.
Acceptance of indwelling urinary catheter after extraction of the catheter1 weekPatients will be asked to answer the question Will you worry about urinary catheterization if you undergo another operation next time?. The answer No meant acceptance of indwelling urinary catheter, and the answer Yes meant unacceptance of indwelling urinary catheter.
Postoperative sufentanil requirement1 dayIntravenous sufentanil 5 μg will be administered as rescue analgetic treatment for postoperative pain, and sufentanil requirementwill be recorded and compared.

Countries

China

Contacts

Primary ContactRen Liao, M.D.
liaoren7733@163.com+86-18980602177

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 12, 2026